» Articles » PMID: 35336859

Angiotensin Converting Enzyme Inhibitors May Increase While Active Vitamin D May Decrease the Risk of Severe Pneumonia in SARS-CoV-2 Infected Patients with Chronic Kidney Disease on Maintenance Hemodialysis

Abstract

The group most at risk of death due to COVID-19 are patients on maintenance hemodialysis (HD). The study aims to describe the clinical course of the early phase of SARS-CoV-2 infection and find predictors of the development of COVID-19 severe pneumonia in this population. This is a case series of HD nonvaccinated patients with COVID-19 stratified into mild pneumonia and severe pneumonia group according to the chest computed tomography (CT) pneumonia total severity score (TSS) on admission. Epidemiological, demographic, clinical, and laboratory data were obtained from hospital records. 85 HD patients with a mean age of 69.74 (13.19) years and dialysis vintage of 38 (14-84) months were included. On admission, 29.14% of patients had no symptoms, 70.59% reported fatigue followed by fever-44.71%, shortness of breath-40.0%, and cough-30.59%. 20% of the patients had finger oxygen saturation less than 90%. In 28.81% of patients, pulmonary parenchyma was involved in at least 25%. The factors associated with severe pneumonia include fever, low oxygen saturation and arterial partial pressure of oxygen, increased C-reactive protein and ferritin serum levels, low blood count of lymphocytes as well as chronic treatment with angiotensin converting enzyme inhibitors; while the chronic active vitamin D treatment was associated with mild pneumonia. In conclusion, even though nearly one-third of the patients were completely asymptomatic, while the remaining usually reported only single symptoms, a large percentage of them had extensive inflammatory changes at diagnosis with SARS-CoV-2 infection. We identified potential predictors of severe pneumonia, which might help individualize pharmacological treatment and improve clinical outcomes.

Citing Articles

Incorporation of Chest Computed Tomography Quantification to Predict Outcomes for Patients on Hemodialysis with COVID-19.

Xing H, Gu S, Li Z, Wei X, He L, Liu Q Kidney Dis (Basel). 2024; 10(4):284-294.

PMID: 39131882 PMC: 11309758. DOI: 10.1159/000539568.


The Efficacy and Safety of High-Dose Cholecalciferol Therapy in Hemodialysis Patients.

Tarasewicz A, Komorniczak M, Zakrzewska A, Biedunkiewicz B, Malgorzewicz S, Jankowska M Biomedicines. 2024; 12(2).

PMID: 38397979 PMC: 10886943. DOI: 10.3390/biomedicines12020377.


COVID-19 Infection and Response to Vaccination in Chronic Kidney Disease and Renal Transplantation: A Brief Presentation.

Stai S, Lioulios G, Christodoulou M, Kasimatis E, Fylaktou A, Stangou M Life (Basel). 2022; 12(9).

PMID: 36143394 PMC: 9505388. DOI: 10.3390/life12091358.


Vitamin D for Recovery of COVID-19 in Patients With Chronic Kidney Disease.

Chiang W, Hsiao P, Chan J Front Nutr. 2022; 9:930176.

PMID: 35782942 PMC: 9240470. DOI: 10.3389/fnut.2022.930176.


The severity of the second wave of SARS CoV-2 in maintenance dialysis patients of a single center in Brazil.

Gorayeb-Polacchini F, Caldas H, Abbud-Filho M Ren Fail. 2022; 44(1):748-751.

PMID: 35509194 PMC: 9090360. DOI: 10.1080/0886022X.2022.2069580.

References
1.
Ojo A, Balogun S, Williams O, Ojo O . Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies. Pulm Med. 2020; 2020:6175964. PMC: 7439160. DOI: 10.1155/2020/6175964. View

2.
Chauss D, Freiwald T, McGregor R, Yan B, Wang L, Nova-Lamperti E . Autocrine vitamin D signaling switches off pro-inflammatory programs of T1 cells. Nat Immunol. 2021; 23(1):62-74. PMC: 7612139. DOI: 10.1038/s41590-021-01080-3. View

3.
Bayraktaroglu S, Cinkooglu A, Ceylan N, Savas R . The novel coronavirus pneumonia (COVID-19): a pictorial review of chest CT features. Diagn Interv Radiol. 2020; 27(2):188-194. PMC: 7963373. DOI: 10.5152/dir.2020.20304. View

4.
Stumpf J, Siepmann T, Lindner T, Karger C, Schwobel J, Anders L . Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur. 2021; 9:100178. PMC: 8299287. DOI: 10.1016/j.lanepe.2021.100178. View

5.
Ramakrishnan S, Nicolau Jr D, Langford B, Mahdi M, Jeffers H, Mwasuku C . Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021; 9(7):763-772. PMC: 8040526. DOI: 10.1016/S2213-2600(21)00160-0. View